Blog

[:content [\5 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \T \h \e \space \p \C \O \D \R \space \E \x \p \e \r \t \space \R \e \v \i \e \w \space \C \o \m \m \i \t \t \e \e \space \( \p \E \R \C \) \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \space \f \u \n \d \i \n \g \space \o \f \space \d \a \b \r \a \f \e \n \i \b \space \m \e \s \y \l \a \t \e \space \( \T \a \f \i \n \l \a \r \) \space \i \n \space \C \a \n \a \d \a " ..."]]

The Simplified Price Disclosure page has been updated. The page now includes an explanation of the steps for the price disclosure calculation ...

The agenda for the 11 June 2014 Transparency Commission meeting is now available.  The Commission will examine the following health ...

The deadline for submitting abstracts for panels, oral presentations and poster for the 2015 CADTH Symposium (TCU Place, Saskatoon – ...

Galderma Canada Inc. today announced the Health Canada approval of Rosiver (ivermectin) cream 1%, a once-daily topical treatment for inflammatory ...

[:content [\T \h \e \space \A \f \f \o \r \d \a \b \l \e \space \C \a \r \e \space \A \c \t \space \o \f \f \e \r \s \space \s \t \r \o \n \g \space \s \u \p \p \o \r \t \space \f \o \r \space \c \o \m \p \a \r \a \t \i \v \e \space \e \f \f \e \c \t \i \v \e \n \e \s \s \space \r \e \s \e \a \r \c \h \, \space \w \h \i \c \h \space \e \n \t \a \i \l \s \space \c \o \m \p \a \r \i \s \o \n \s \space \a \m \o \n \g \space \a \c \t \i \v \e \space \t \r \e \a \t \m \e \n \t \s \, \space \t \o \space \p \r \o \v \i \d \e \space \t \h \e " ..."]]

[:content [\N \I \C \E \space \h \a \s \space \p \u \b \l \i \s \h \e \d \  \f \i \n \a \l \space \d \r \a \f \t \space \g \u \i \d \a \n \c \e \space \r \e \c \o \m \m \e \n \d \i \n \g \space \a \f \l \i \b \e \r \c \e \p \t \  \s \o \l \u \t \i \o \n \space \f \o \r \space \i \n \j \e \c \t \i \o \n \  \a \s \space \a \n \space \o \p \t \i \o \n \space \f \o \r \space \t \r \e \a \t \i \n \g \space \w \e \t \space \a \g \e \- \r \e \l \a \t \e \d \space \m \a \c \u \l \a \r \space \d \e \g \e \n \e \r \a \t \i \o \n \space \( \A \M \D \) \. \  \A \f \l \i \b \e \r \c \e \p \t \space \i \s \space \r \e \c \o \m \m \e \n \d \e \d " ..."]]

PHARMAC is seeking feedback on a proposal to widen access to tocilizumab in DHB hospitals from 1 January 2015 for ...

Alberta’s health minister has reached a tentative deal that will allow provinces to cover the costs of an expensive cystic ...

[:content [\I \n \t \e \r \e \s \t \i \n \g \space \e \d \i \t \o \r \i \a \l \space \b \y \space \A \l \a \n \space \M \a \y \n \a \r \d \space \i \n \space \t \h \e \space \M \a \y \space \2 \0 \1 \3 \space \i \s \s \u \e \space \o \f \space \P \h \a \r \m \a \c \o \E \c \o \n \o \m \i \c \s \. " ..."]]

Big drug companies have come under fire from the Federal Government for pushing expensive cancer medications that have limited benefit. ...

Boehringer Ingelheim today announced that following a review by the National Institute for Health and Care Excellence (NICE) in the ...

A breast cancer treatment that can cost more than £90,000 per patient is not effective enough to justify the price ...